Added to YB: 2025-10-27
Pitch date: 2025-10-23
ABCL [bullish]
AbCellera Biologics Inc.
-39.9%
current return
Author Info
No bio for this author
Company Info
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Market Cap
$1.6B
Pitch Price
$5.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.86
P/E
-9.77
EV/Sales
37.22
Sector
Life Sciences Tools and Services
Category
turnaround
The Picture of Peter Thiel - AbCellera Biologics Inc.
ABCL: AI-powered antibody discovery platform transitioning from service provider to full-stack drug developer. Two flagship programs (ABCL635 hot flashes >$2B TAM, ABCL575 eczema >$11B TAM) entering Phase 1 trials H1'26. ~$750M liquidity provides 5+ years runway. Manufacturing facility completion by '25YE adds contract revenue upside.
Read full article (5 min)